

CONTD FROM PAGE 62



With Mr. M Shah VP, Finance, Alembic

leader in macrolides segment of anti-infective drugs in India. With about 9000 employees, the company now sells more than 100 products in the United States, representing more than 400+ SKUs under its own label. Alembic intends to launch 15 to 20 products each year over the next 3 years. In addition, Alembic now have fully operational oncology injectable facility. In total, Alembic has 100+ ongoing projects, which include targets in dermatology, injectable, and ophthalmic

In Ahmedabad, we also visited Indian Pharmaceutical Leading companies top leadership to be the part of this new initiative, Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company, which is primarily engaged in the manufacture of generic drugs. It featured in the Fortune India 500 list in 2020. Cadila was founded in 1952 by Ramanbhai Patel (1925-2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company. Zydus today is a Leader in Pharmaceuticals manufacturing as a Billion-dollar company. Me along with my advisors on board had meeting with Dr. Keyur Parekh, Sr. VP and Lead Strategist. we had an opportunity to visit their center of science and innovation as well.



with Dr. Keyur Parekh, Sr. VP, Zydex

We are in continuation to our meetings for the 2023, US India Healthcare Summit and understanding the companies visited Vadodara HQ of Sun Pharmaceuticals. Already the world's third-largest manufacturer of medicines by volume, India has one of the lowest manufacturing costs globally. About one in three pills consumed in the U.S. and one in four in the

U.K. are made in India. However, India's \$42 billion pharmaceutical sector is heavily dependent on China for key active pharmaceutical ingredients or API - chemicals that are responsible for the therapeutic effect of drugs.

The 2014 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 4th largest specialty generic company globally. It's having a revenue of \$5 billion with 37,000 + employees. Me along with Anand Krishnamurthy and team talked about usage of AI and ML in Pharmacovigilance, cyber security, and data protection. We also talked about the applications for sales and marketing, supply chain, manufacturing and its usage in drug development process and its command and control. We met Mr. A.S. Sajam, Head Administration along with others including representation from FDAC.



Meeting with Mr. A.S. Sajam, Head, Adm and team at Sun Pharma

In continuing our efforts to meet the top Indian Pharmaceutical manufacturers for GITCC USA for US India Healthcare Summit 2023. Mr. H S Panaser and Mr. Anand Krishnamurthy and T. Srinivas visited Hyderabad. We met Mr. T Srinivas CFP, Bharat Biotech, a 700 plus employee company The company has been responsible for developing COVAX which is a whole inactivated virus-based vaccine 19 developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC. They were one of the first to develop vaccines for viral diseases like Chikungunya and Zika. The company also produces vaccines for Japanese Encephalitis.[13] Bharat Biotech has biosafety level 3



With Mr. T Srinivas, CFO, Bharat Biotech

(BSL3) laboratories.

Hetero Drugs and had a meeting with their Chairman Dr. B P S Reddy, also the Member of Parliament, India and the Managing Director Dr. V K Reddy. Today, Hetero has Asia's Largest API SEZ manufacturing complex for APIs - with 1,000+ reactors and spread over 500 acres. Hetero has over 36 strategically located, manufacturing facilities catering to diverse market requirements on demand - including India, USA, China, Russia, Egypt, Mexico, Indonesia and Saudi Arabia.



With Mr. B P S Reddy, MP, Chair Hetro Pharma and with Mr. V K Reddy, MD, Hetro Pharma

\*1: <https://www.ibef.org/exports/pharmaceutical-exports-from-india#:~:text=India%20Pharma%20Exports%20and%20Advantage%20India&text=India%20has%20exported%20US%24%203.89,US%24%201.97%20in%20August%202020>.

\*2: <https://www.orfonline.org/expert-speak/time-to-end-the-battle-of-indian-pharmaceutical-players-and-chinese-key-ingredients/>

\*3: [https://www.ibef.org/download/PLI\\_schemeRevised.pdf](https://www.ibef.org/download/PLI_schemeRevised.pdf)

(H. S. Panaser is a Global Marketing and Business Development Consultant, Speaker and EDP Trainer. He is Chairman, GITCC, USA. He can be reached at [hspanaser@gmail.com](mailto:hspanaser@gmail.com) US phone 1- 732-266-2027)